NCT05100134 2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available
Clinical Trials
20 trialsNCT04741789 2026-03-16
Managed Access Programs for INC280, Capmatinib
Novartis
No longer available
NCT03756311 2026-01-23
Expanded Access to NanoPac
NanOlogy, LLC
No longer available
NCT06841874 2025-12-24
Tale EAP
Nuvation Bio Inc.
No longer available
NCT04667234 2025-08-13
Expanded Access of Sotorasib
Amgen
No longer available
NCT06099639 2025-06-08
Medical Access Program for Patritumab Deruxtecan
Daiichi Sankyo
No longer available
NCT04507919 2024-11-12
Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer
Novartis
No longer available
NCT03874455 2024-03-22
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Ipsen
No longer available
NCT05225259 2024-02-28
Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor
Eli Lilly and Company
No longer available
NCT02475382 2020-11-27
CheckMate 169
Bristol-Myers Squibb
No longer available
NCT01947608 2020-11-03
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Novartis
No longer available
NCT03554434 2020-03-02
An Expanded Access Program for AM0010 (Pegilodecakin)
Eli Lilly and Company
No longer available
NCT03178071 2019-11-04
Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Pfizer
No longer available
NCT03503890 2019-09-10
Expanded Access to Rovalpituzumab Tesirine
AbbVie
No longer available
NCT02547675 2018-09-25
Rociletinib (CO-1686) USA Expanded Access Program
Clovis Oncology, Inc.
No longer available
NCT02784158 2018-02-06
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Takeda
No longer available
NCT02824094 2017-07-21
Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC
Pfizer
No longer available
NCT02271139 2017-03-09
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
Genentech, Inc.
No longer available
NCT02451852 2016-07-14
AZD9291 US Expanded Access Program
AstraZeneca
No longer available
NCT01279798 2011-03-01
Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)
NovaRx Corporation
No longer available